244 related articles for article (PubMed ID: 25786035)
1. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists.
Koukoui F; Desmoulin F; Galinier M; Barutaut M; Caubère C; Evaristi MF; Murat G; De Boer R; Berry M; Smih F; Rouet P
PLoS One; 2015; 10(3):e0119160. PubMed ID: 25786035
[TBL] [Abstract][Full Text] [Related]
2. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.
Fiuzat M; Schulte PJ; Felker M; Ahmad T; Neely M; Adams KF; Donahue MP; Kraus WE; Piña IL; Whellan DJ; O'Connor CM
J Card Fail; 2014 Jan; 20(1):38-44. PubMed ID: 24304938
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of aldosterone and cortisol in patients hospitalized for acutely decompensated chronic heart failure with and without mineralocorticoid receptor antagonism.
Güder G; Hammer F; Deutschbein T; Brenner S; Berliner D; Deubner N; Bidlingmaier M; Ertl G; Allolio B; Angermann CE; Fassnacht M; Störk S
J Card Fail; 2015 Mar; 21(3):208-16. PubMed ID: 25573831
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction.
Gandhi PU; Motiwala SR; Belcher AM; Gaggin HK; Weiner RB; Baggish AL; Fiuzat M; Brunner-La Rocca HP; Januzzi JL
Am Heart J; 2015 Mar; 169(3):404-411.e3. PubMed ID: 25728731
[TBL] [Abstract][Full Text] [Related]
5. Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure.
Bistola V; Simitsis P; Farmakis D; Ikonomidis I; Bakosis G; Triposkiadis F; Hatziagelaki E; Lekakis J; Mebazaa A; Parissis J
Clin Res Cardiol; 2018 Jan; 107(1):76-86. PubMed ID: 28921054
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
[TBL] [Abstract][Full Text] [Related]
7. sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure.
Barutaut M; Fournier P; Peacock WF; Evaristi MF; Dambrin C; Caubère C; Koukoui F; Galinier M; Smih F; Rouet P
Acta Cardiol; 2020 Dec; 75(8):739-747. PubMed ID: 31560863
[No Abstract] [Full Text] [Related]
8. Renal function largely influences Galectin-3 prognostic value in heart failure.
Zamora E; Lupón J; de Antonio M; Galán A; Domingo M; Urrutia A; Troya M; Bayes-Genis A
Int J Cardiol; 2014 Nov; 177(1):171-7. PubMed ID: 25499371
[TBL] [Abstract][Full Text] [Related]
9. Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure.
Rossi R; Crupi N; Coppi F; Monopoli D; Sgura F
J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):119-25. PubMed ID: 23539659
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure.
Clemenza F; Masson S; Conaldi PG; Di Carlo D; Boccanelli A; Mureddu GF; Gonzini L; Lucci D; Maggioni AP; Di Lenarda A; Nicolis EB; Vanasia M; Latini R;
Circ J; 2017 Sep; 81(10):1543-1546. PubMed ID: 28855452
[TBL] [Abstract][Full Text] [Related]
11. Utilization pattern of mineralocorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: a single-center experience.
Chamsi-Pasha MA; Dupont M; Al Jaroudi WA; Tang WH
J Card Fail; 2014 Apr; 20(4):229-35. PubMed ID: 24486929
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience.
Sygitowicz G; Tomaniak M; Filipiak KJ; Kołtowski Ł; Sitkiewicz D
Adv Clin Exp Med; 2016; 25(4):617-23. PubMed ID: 27629834
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction.
Suzuki S; Motoki H; Kanzaki Y; Maruyama T; Hashizume N; Kozuka A; Yahikozawa K; Kuwahara K
ESC Heart Fail; 2020 Oct; 7(5):2752-2761. PubMed ID: 32592265
[TBL] [Abstract][Full Text] [Related]
14. Metabolic profile provides prognostic value better than galectin-3 in patients with heart failure.
Wang CH; Cheng ML; Liu MH; Kuo LT; Shiao MS
J Cardiol; 2017 Jul; 70(1):92-98. PubMed ID: 28318874
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
Ferreira JP; Rossignol P; Machu JL; Sharma A; Girerd N; Anker SD; Cleland JG; Dickstein K; Filippatos G; Hillege HL; Lang CC; Ter Maaten JM; Metra M; Ng L; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Voors A; Zannad F
Eur J Heart Fail; 2017 Oct; 19(10):1284-1293. PubMed ID: 28580625
[TBL] [Abstract][Full Text] [Related]
16. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study.
Blankenburg M; Fett AK; Eisenring S; Haas G; Gay A
BMC Nephrol; 2019 May; 20(1):171. PubMed ID: 31096928
[TBL] [Abstract][Full Text] [Related]
17. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure).
Boccanelli A; Cacciatore G; Mureddu GF; de Simone G; Clemenza F; De Maria R; Di Lenarda A; Gavazzi A; Latini R; Masson S; Porcu M; Vanasia M; Gonzini L; Maggioni AP
J Cardiovasc Med (Hagerstown); 2007 Sep; 8(9):683-91. PubMed ID: 17700397
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.
Leone M; Iacoviello M
Minerva Cardioangiol; 2016 Apr; 64(2):181-94. PubMed ID: 26426300
[TBL] [Abstract][Full Text] [Related]
19. Clinical Presentation, Predictors, and Outcomes Among Mineralocorticoid Receptor Antagonist (MRA)-Eligible Acute Heart Failure Patients in the Heart Function Assessment Registry Trial in Saudi Arabia (HEARTS).
AlShamiri MQ; AlHabib KF; AlHabeeb W; Raslan IR; Ullah A; Elasfar AA; Alshaer F; Albackr H; Mimish L; Almasood A; AlGhamdi S; Ghabashi A
Angiology; 2018 Apr; 69(4):323-332. PubMed ID: 28750542
[TBL] [Abstract][Full Text] [Related]
20. Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure.
Wang CH; Yang NI; Liu MH; Hsu KH; Kuo LT
Cardiol J; 2016; 23(5):563-572. PubMed ID: 27515479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
